Mitochondrial DNA copy number and incident heart failure:

The Atherosclerosis Risk in Communities (ARIC) study

Short title: mitochondrial DNA copy number and incident heart failure

Yun Soo Hong, MD, MHS,¹ Ryan J. Longchamps, BS,² Di Zhao, PhD,¹ Christina A. Castellani,² PhD, Laura R. Loehr, MD, PhD,³ Patricia P. Chang, MD, MHS,³ Kunihiro Matsushita, MD, PhD,¹ Megan L. Grove, MS,⁴ Eric Boerwinkle, PhD,^{4,5} Dan E. Arking, PhD², Eliseo Guallar, MD, DrPH¹

¹ Departments of Epidemiology and Medicine, and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University Bloomberg School of Public Health. Baltimore, Maryland, USA.

² McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

³ Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

⁵ Human Genetics Center, Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

⁶ Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.

Address for correspondence: Dan E. Arking, PhD, Johns Hopkins University School of

Medicine, 733 N. Broadway, Miller Research Bldg, Room 447, Baltimore, Maryland, USA,

21205. Tel: (410) 502-4867, Fax: (410) 614-8600; E-mail: arking@jhmi.edu.

Co-correspondence: Eliseo Guallar, MD, DrPH, Welch Center for Prevention, Epidemiology

and Clinical Research, Johns Hopkins University Bloomberg School of Public Health, 2024 E.

Monument Street, Room 2-645, Baltimore, MD 21205. Tel. + (1) 410-614-0574. Fax + (1) 410-

955-0476. E-mail eguallar@jhu.edu.

Total word count: 5,801 words

ABSTRACT

Background: The association between mitochondrial DNA-copy number (mtDNA-CN) and incident heart failure (HF) in the general population is unclear.

Methods: We examined the association between mtDNA-CN and the risk of incident HF among 10,802 participants free of HF at baseline from the Atherosclerosis Risk in Communities (ARIC) study, a large bi-racial population-based cohort. mtDNA-CN was estimated using probe intensities on the Affymetrix Genome-Wide Human single nucleotide polymorphisms Array 6.0. Incident HF events were identified through hospital discharge codes from 1987 until 2005 and through adjudication by the ARIC HF Classification Committee since 2005.

Results: During a median follow-up of 23.1 years, there were 2,227 incident HF events (incidence rate 10.3 per 1000 person-years). In fully adjusted models, the hazard ratios (95% confidence intervals) for HF comparing the 2nd through 5th quintiles of mtDNA-CN to the 1st quintile were 0.91 (0.80–1.04), 0.82 (0.72–0.93), 0.81 (0.71–0.92), and 0.74 (0.65–0.85), respectively (*P* for trend < 0.001). In stratified analyses, the associations between mtDNA-CN and HF were similar across examined subgroups. The inverse association between mtDNA-CN and incident HF was stronger in HF with reduced ejection fraction (HFrEF) than in HF with preserved ejection fraction (HFpEF).

Conclusions: In this prospective cohort, mtDNA-CN was inversely associated with the risk of incident HF suggesting that reduced levels of mtDNA-CN, a biomarker of mitochondrial dysfunction, could reflect early susceptibility to HF.

Keywords: cohort study; heart failure; mitochondrial DNA; mitochondrial DNA copy number; mitochondrial dysfunction.

INTRODUCTION

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Heart failure (HF) is a leading clinical and public health concern affecting 23 million people globally and 6.2 million adults in the United States alone. 1,2 The lifetime risk of developing HF is 20% and the prevalence of HF in the US is expected to increase by nearly 50% by the year 2030.^{3,4} Despite recent improvements, the prognosis of HF is still poor, with 5-year mortality >40%. 5-8 Thus, it is critical to identify novel pathways that can help design new preventive strategies and characterize subjects at high risk of developing HF. Mitochondria generate nearly all energy used by the cell as adenosine triphosphate (ATP). Each mitochondrion has 2 to 10 copies of mitochondrial DNA (mtDNA), for a total of 10³ to 10⁴ copies of mtDNA per cell. mtDNA copy number (mtDNA-CN) changes with energy demands and with oxidative stress, and has been established as an indirect biomarker of mitochondrial dysfunction. 10,11 Reduced mtDNA-CN measured in peripheral blood is associated with cardiovascular disease (CVD), all-cause mortality, hypertension, diabetes, chronic kidney disease, and sudden cardiac death. 12-18 In a case-control study, hospitalized patients with HF had lower mtDNA-CN in peripheral blood compared to controls without HF, and when HF cases were followed up, those with lower mtDNA-CN had a higher risk of cardiovascular death and rehospitalization compared to those with higher mtDNA-CN. 19 In small case-control studies, depletion of mtDNA in heart tissue samples was associated with HF. 20,21 The association between mtDNA-CN and incident HF in the general population, however, is unknown. In the present study, we examined the association between baseline mtDNA-CN and the risk of incident HF in the Atherosclerosis Risk in Communities (ARIC) study, a large bi-racial population-based cohort.

MATERIALS AND METHODS

Study population

The ARIC study is a population-based prospective cohort of 15,792 individuals 45–65 years of age at the time of recruitment (1987–1989; Visit 1). ARIC participants were recruited from 4 US communities: Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and Washington County, MD.²² Since the first study visit, there have been 6 subsequent in-person visits (visits 2–7, with visit 7 currently underway) and regular telephone interviews (annually and then semiannually since 2012). Our analysis was restricted to 11,453 White or Black participants who had DNA collected in one of the visits to generate mtDNA-CN measurements (Supplementary Figure 1). We then excluded Black participants recruited from Minnesota or Maryland (n = 1), participants without follow-up information (n = 1), and participants with prevalent HF at the time of DNA collection (n = 596). We further excluded participants missing information on body mass index (n = 17) and high-density lipoprotein (HDL) cholesterol (n = 14). The final sample included 10,802 participants (4,918 men and 5,904 women without HF at the time of DNA sampling). All centers obtained approval from their respective institutional review boards and all participants provided written informed consent.

Measurements

ARIC participants underwent a comprehensive cardiovascular examination and interview by trained clinical staff members during each clinic visit. Age, sex, race/ethnicity, smoking status, alcohol intake, and medication history were self-reported. Smoking and alcohol intake were categorized as never, former, and current. Body mass index (BMI) was calculated from measured height and weight and categorized as underweight/normal (<25 kg/m²), overweight

Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current use of anti-hypertensive medication. Diabetes was defined as self-reported physician diagnosis of diabetes, fasting glucose ≥126 mg/dL, non-fasting glucose ≥200 mg/dL, or use of hypoglycemic medication. Prevalent coronary heart disease (CHD) was defined as the presence of a myocardial infarction based on self-report or electrocardiogram in visit 1, or the development of an adjudicated definite or probable myocardial infarction prior to the time of DNA collection for mtDNA-CN measurement.

Measurement of mtDNA copy number

The methods for measuring mtDNA-CN have been described previously. ^{17,23} Briefly, DNA was extracted using the Gentra Puregene Blood Kit (Qiagen N.V., Venlo, The Netherlands) from buffy coat of whole blood samples collected in visits 1–4. mtDNA-CN was calculated from probe intensities of mitochondrial single nucleotide polymorphisms (SNP) on the Affymetrix Genome-Wide Human SNP Array 6.0 using the Genvisis software package (www.genvisis.org), which uses the median mitochondrial probe intensity of 25 high-quality mitochondrial probes as initial raw measure of mtDNA-CN. Batch effects, DNA quality, and starting DNA quantity were corrected for by using surrogate variable analysis applied to probe intensities of 43,316 autosomal SNPs. ²⁴ The mtDNA-CN metric used in this analysis was obtained as the standardized residuals (mean 0 and standard deviation 1) in a linear regression in which initial raw estimates of mtDNA-CN were regressed against age, sex, enrollment center, surrogate variables used in the surrogate variable analysis, and white blood cell count. White

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

4

was first categorized into quintiles based on the overall sample distribution. In secondary

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

5

cases that occurred since January 1, 2005. For the two analyses restricted to events since 2005,

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

6

subgroups defined by age, sex, race, smoking status, and history of CHD (Figure 2). The

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

8

apoptotic pathways, inflammatory mediators, and matrix metalloproteinases. 34,42,43 This process

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

9

analyses based on discharge codes and for those based on adjudicated events.²⁵ Third, our

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

with different types of HF and their severity.

1

3

4

2 The authors thank the staff and participants of the ARIC study for their important contributions.

SOURCES OF FUNDING

- 5 US National Institutes of Health grants (R01HL131573 to E.G., R.J.L., C.A.C., D.E.A.; and
- 6 R01HL111267 to R.J.L., D.E.A.). The Atherosclerosis Risk in Communities study has been
- 7 funded in whole or in part with Federal funds from the National Heart, Lung, and Blood
- 8 Institute, National Institutes of Health, Department of Health and Human Services (contract
- 9 numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I,
- 10 HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL059367,
- R01HL086694; National Human Genome Research Institute contract U01HG004402; and
- National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported
- by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH
- 14 Roadmap for Medical Research.

REFERENCES

- 2 1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure.
- 3 Nature reviews Cardiology 2011;8:30-41.
- 4 2. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke
- 5 Statistics—2019 Update: A Report From the American Heart Association. Circulation
- 6 2019;139:e56-e528.
- 7 3. Metra M, Teerlink JR. Heart failure. Lancet (London, England) 2017;390:1981-95.
- 8 4. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive
- 9 heart failure: the Framingham Heart Study. Circulation 2002;106:3068-72.
- 10 5. Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart
- 11 Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across
- regions. European journal of heart failure 2016;18:613-25.
- 13 6. Chang PP, Chambless LE, Shahar E, et al. Incidence and survival of hospitalized acute
- decompensated heart failure in four US communities (from the Atherosclerosis Risk in
- 15 Communities Study). The American journal of cardiology 2014;113:504-10.
- 16 7. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure
- 17 incidence and survival (from the Atherosclerosis Risk in Communities study). The American
- 18 journal of cardiology 2008;101:1016-22.
- 19 8. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure
- 20 epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA internal medicine 2015;175:996-
- 21 1004.
- 22 9. Friedman JR, Nunnari J. Mitochondrial form and function. Nature 2014;505:335-43.

- 1 10. Clay Montier LL, Deng JJ, Bai Y. Number matters: control of mammalian mitochondrial
- 2 DNA copy number. Journal of genetics and genomics = Yi chuan xue bao 2009;36:125-31.
- 3 11. Malik AN, Czajka A. Is mitochondrial DNA content a potential biomarker of
- 4 mitochondrial dysfunction? Mitochondrion 2013;13:481-92.
- 5 12. Zhang Y, Guallar E, Ashar FN, et al. Association between mitochondrial DNA copy
- 6 number and sudden cardiac death: findings from the Atherosclerosis Risk in Communities study
- 7 (ARIC). European heart journal 2017;38:3443-8.
- 8 13. Ashar FN, Zhang Y, Longchamps RJ, et al. Association of Mitochondrial DNA Copy
- 9 Number With Cardiovascular Disease. JAMA cardiology 2017;2:1247-55.
- 10 14. Ashar FN, Moes A, Moore AZ, et al. Association of mitochondrial DNA levels with
- frailty and all-cause mortality. Journal of molecular medicine (Berlin, Germany) 2015;93:177-
- 12 86.
- 13 15. Tang X, Luo YX, Chen HZ, Liu DP. Mitochondria, endothelial cell function, and
- vascular diseases. Frontiers in physiology 2014;5:175.
- 15 16. Lee HK, Song JH, Shin CS, et al. Decreased mitochondrial DNA content in peripheral
- blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes research
- 17 and clinical practice 1998;42:161-7.
- 18 17. Tin A, Grams ME, Ashar FN, et al. Association between Mitochondrial DNA Copy
- 19 Number in Peripheral Blood and Incident CKD in the Atherosclerosis Risk in Communities
- 20 Study. Journal of the American Society of Nephrology: JASN 2016;27:2467-73.
- 21 18. Yue P, Jing S, Liu L, et al. Association between mitochondrial DNA copy number and
- 22 cardiovascular disease: Current evidence based on a systematic review and meta-analysis. PloS
- 23 one 2018;13:e0206003.

- 1 19. Huang J, Tan L, Shen R, Zhang L, Zuo H, Wang DW. Decreased Peripheral
- 2 Mitochondrial DNA Copy Number is Associated with the Risk of Heart Failure and Long-term
- 3 Outcomes. Medicine 2016;95:e3323.
- 4 20. Karamanlidis G, Nascimben L, Couper GS, Shekar PS, del Monte F, Tian R. Defective
- 5 DNA replication impairs mitochondrial biogenesis in human failing hearts. Circulation research
- 6 2010;106:1541-8.
- 7 21. Karamanlidis G, Bautista-Hernandez V, Fynn-Thompson F, Nido Pd, Tian R. Impaired
- 8 Mitochondrial Biogenesis Precedes Heart Failure in Right Ventricular Hypertrophy in
- 9 Congenital Heart Disease. 2011;4:707-13.
- 10 22. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The
- ARIC investigators. American journal of epidemiology 1989;129:687-702.
- 12 23. Longchamps R, Castellani C, Newcomb C, et al. Evaluation of mitochondrial DNA copy
- number estimation techniques. bioRxiv 2019:610238.
- 14 24. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing
- batch effects and other unwanted variation in high-throughput experiments. Bioinformatics
- 16 (Oxford, England) 2012;28:882-3.
- 17 25. Rosamond WD, Chang PP, Baggett C, et al. Classification of heart failure in the
- atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria.
- 19 Circulation Heart failure 2012;5:152-9.
- 20 26. Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the
- 21 Cox model: Stata College Station, Texas; 2011.

- 1 27. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction
- 2 associated with oxidative stress in failing hearts after myocardial infarction. Circulation research
- 3 2001;88:529-35.
- 4 28. Ikeuchi M, Matsusaka H, Kang D, et al. Overexpression of mitochondrial transcription
- 5 factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction.
- 6 Circulation 2005;112:683-90.
- 7 29. Wang J, Wilhelmsson H, Graff C, et al. Dilated cardiomyopathy and atrioventricular
- 8 conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression.
- 9 Nature genetics 1999;21:133-7.
- 10 30. Kuznetsova T, Knez J. Peripheral Blood Mitochondrial DNA and Myocardial Function.
- In: Santulli G, ed. Mitochondrial Dynamics in Cardiovascular Medicine. Cham: Springer
- 12 International Publishing; 2017:347-58.
- 13 31. Ahuja P, Wanagat J, Wang Z, et al. Divergent mitochondrial biogenesis responses in
- human cardiomyopathy. Circulation 2013;127:1957-67.
- 15 32. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management
- of heart failure: a report of the American College of Cardiology Foundation/American Heart
- 17 Association Task Force on Practice Guidelines. Journal of the American College of Cardiology
- 18 2013;62:e147-239.
- 19 33. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and
- treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of
- acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the
- special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal
- 23 2016;37:2129-200.

- 1 34. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. American
- 2 journal of physiology Heart and circulatory physiology 2011;301:H2181-90.
- 3 35. Tsutsui H, Kinugawa S, Matsushima S. Oxidative Stress and Mitochondrial DNA
- 4 Damage in Heart Failure. Circulation Journal 2008;72:A31-A7.
- 5 36. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling.
- 6 Hypertension (Dallas, Tex: 1979) 2007;49:241-8.
- 7 37. Marín-García JJHFR. Mitochondrial DNA repair: a novel therapeutic target for heart
- 8 failure. 2016;21:475-87.
- 9 38. Munzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC. Impact of Oxidative
- 10 Stress on the Heart and Vasculature: Part 2 of a 3-Part Series. Journal of the American College of
- 11 Cardiology 2017;70:212-29.
- 12 39. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and
- 13 ROS-induced ROS release. Physiological reviews 2014;94:909-50.
- 14 40. Cline SD. Mitochondrial DNA damage and its consequences for mitochondrial gene
- expression. Biochimica et biophysica acta 2012;1819:979-91.
- 16 41. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists
- 17 longer than nuclear DNA damage in human cells following oxidative stress. Proceedings of the
- National Academy of Sciences of the United States of America 1997;94:514-9.
- 19 42. Casademont J, Miro O. Electron transport chain defects in heart failure. Heart failure
- 20 reviews 2002;7:131-9.
- 21 43. Verdejo HE, del Campo A, Troncoso R, et al. Mitochondria, myocardial remodeling, and
- cardiovascular disease. Current hypertension reports 2012;14:532-9.

- 2 Arteriosclerosis, thrombosis, and vascular biology 2005;25:29-38.
- 3 45. Guzik TJ, Touyz RM. Oxidative Stress, Inflammation, and Vascular Aging in
- 4 Hypertension. Hypertension (Dallas, Tex: 1979) 2017;70:660-7.
- 5 46. Lewis W. Defective mitochondrial DNA replication and NRTIs: pathophysiological
- 6 implications in AIDS cardiomyopathy. American journal of physiology Heart and circulatory
- 7 physiology 2003;284:H1-9.
- 8 47. Nitiss KC, Nitiss JL. Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial
- 9 DNA damage. Clinical cancer research: an official journal of the American Association for
- 10 Cancer Research 2014;20:4737-9.

16

- 11 48. Lebrecht D, Walker UA. Role of mtDNA lesions in anthracycline cardiotoxicity.
- 12 Cardiovascular toxicology 2007;7:108-13.
- 13 49. Knez J, Lakota K, Bozic N, et al. Correlation Between Mitochondrial DNA Content
- Measured in Myocardium and Peripheral Blood of Patients with Non-Ischemic Heart Failure.
- 15 Genetic testing and molecular biomarkers 2017;21:736-41.

1

10

- 2 **Figure 1.** Hazard ratios for incident heart failure by levels of mitochondrial DNA copy number.
- 3 The curves represent adjusted hazard ratios (solid line) and their 95% confidence intervals
- 4 (dotted lines) based on restricted quadratic splines of mtDNA copy number with knots at 5th,
- 5 50th, and 95th percentiles of its distribution. The reference value (diamond dot) was set at the 10th
- 6 percentile of the distribution. Results were obtained from a Cox model adjusted for age, sex,
- 7 race/ethnicity, body mass index, smoking, alcohol intake, total and HDL cholesterol, cholesterol
- 8 medication, hypertension, diabetes, and prevalent coronary heart disease. Histograms represent
- 9 the frequency distribution of mtDNA copy number at baseline.
- Figure 2. Hazard ratios for incident heart failure comparing the 90th to the 10th percentile of
- mitochondrial DNA copy number in selected subgroups.
- 13 The figure includes hazard ratios for comparing the 90th to the 10th percentile (reference) of
- 14 mtDNA copy number. Pre-specified subgroups were age (<60 or ≥60 years), sex, race (White or
- 15 Black), smoking status (never, former, or current), alcohol intake (never, former, current), BMI
- 16 (underweight/normal, overweight, or obese), and prevalent CHD. Models were adjusted for age,
- sex, race/ethnicity, body mass index, smoking, alcohol intake, total and HDL cholesterol,
- 18 cholesterol medication, hypertension, diabetes, and prevalent coronary heart disease.
- Figure 3. Time-dependent hazard ratios for incident heart failure comparing the 90th to the 10th
- 21 percentile of mitochondrial DNA copy number.
- 22 The curve represents time-dependent adjusted hazard ratios (solid line) and the gray band
- represents its corresponding 95% confidence interval comparing the 90th to the 10th percentile of

- 1 mtDNA copy number. The dashed line represents the time-fixed adjusted hazard ratio comparing
- 2 the 90th to the 10th percentile of mtDNA copy number. Models were adjusted for age, sex,
- 3 race/ethnicity, body mass index, smoking, alcohol intake, total and HDL cholesterol, cholesterol
- 4 medication, hypertension, diabetes, and prevalent coronary heart disease.

Table 1. Baseline characteristics of study participants by quintile of mitochondrial DNA copy number.

	Overall	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5	<i>P</i> -values [†]
	(n = 10,802)	(n = 2,161)	(n = 2,160)	(n = 2,161)	(n = 2,160)	(n = 2,160)	
mtDNA-CN range	-5.16, 4.84	-5.16, -0.72	-0.72, -0.16	-0.16, 0.29	0.29, 0.78	0.78, 4.84	
Age (year)	57.3 (5.9)	57.3 (6.0)	57.3 (6.1)	57.3 (5.9)	57.2 (5.9)	57.3 (5.8)	0.78
BMI (kg/m ²)	27.8 (5.3)	27.8 (5.4)	27.6 (5.1)	28.1 (5.4)	27.7 (5.3)	27.9 (5.3)	0.78
Male (%)	45.4	45.2	44.9	46.3	44.5	46.2	0.71
Race (%)							0.61
White	79.2	80.3	79.1	78.9	78.3	79.3	
Black	20.8	19.7	20.9	21.2	21.7	20.7	
Smoking (%)							0.02
Never	38.6	36.6	40.2	39.0	38.8	38.5	
Former	38.5	37.7	36.8	38.8	39.7	40.0	
Current	22.7	25.6	23.1	22.2	21.5	21.5	
Current drinker (%)	58.0	55.3	59.0	57.5	61.1	57.9	0.003
TC (mg/dl)	209.7 (39.4)	209.5 (41.7)	208.8 (39.3)	209.3 (37.3)	209.5 (38.0)	211.6 (40.7)	0.07
HDL-C (mg/dl)	49.8 (17.1)	48.4 (16.8)	49.5 (17.1)	49.8 (16.7)	51.2 (17.7)	49.9 (17.2)	< 0.001
$TG (mg/dl)^*$	115 (83–162)	117 (84–164.5)	116 (83–162)	115 (82–165)	109 (81–158)	118 (85–162)	0.003
SBP (mmHg)	122.0 (19.1)	122.7 (19.6)	122.0 (19.9)	122.0 (18.4)	121.6 (18.9)	121.6 (18.6)	0.05
Prevalent CHD (%)	4.8	6.5	5.0	4.8	3.9	4.0	0.001
Hypertension (%)	34.6	37.0	35.1	33.6	33.2	34.5	0.08
Diabetes (%)	14.0	17.3	14.2	13.5	12.1	12.9	< 0.001

Abbreviations: BMI, body mass index; CHD, coronary heart disease; HDL-C, high-density lipoprotein-cholesterol; mtDNA-CN, mitochondrial DNA copy number; SBP, systolic blood pressure; TC, total cholesterol; and TG, triglyceride.

^{*} Median (interquartile range).

[†] P for trend for continuous variables; P values from χ^2 tests for categorical variables.

Table 2. Hazard ratios for incident heart failure by levels of mitochondrial DNA copy number.

mtDNA-CN	N events / N total	Incidence rate per 1,000	Model 1	Model 2	Model 3	Model 4
Overall	2,227 / 10,802	10.3				
Quintile 1	526 / 2,161	12.7	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Quintile 2	455 / 2,160	10.6	0.82 (0.73–0.93)	0.89(0.78-1.01)	0.90 (0.80–1.03)	0.91 (0.80–1.04)
Quintile 3	427 / 2,161	9.9	0.77 (0.68–0.87)	0.79 (0.69–0.89)	0.81 (0.71–0.93)	0.82 (0.72–0.93)
Quintile 4	416 / 2,160	9.3	0.71 (0.63–0.81)	0.77 (0.68–0.88)	0.80 (0.70-0.91)	0.81 (0.71–0.92)
Quintile 5	403 / 2,160	9.2	0.70 (0.62–0.80)	0.74 (0.65–0.84)	0.73 (0.64–0.84)	0.74 (0.65–0.85)
P for trend	·		< 0.001	< 0.001	< 0.001	< 0.001
90 th vs. 10 th percentile			0.71 (0.65–0.78)	0.73 (0.66–0.81)	0.75 (0.68–0.82)	0.76 (0.69–0.84)

Abbreviations: mtDNA-CN, mitochondrial DNA copy number.

Model 1: Adjusted for age, sex, race, and enrollment center; Model 2: Model 1 + body mass index, smoking, and alcohol intake; Model 3: Model 2 + total cholesterol, HDL-cholesterol, cholesterol medication, hypertension, and diabetes; and Model 4: Model 3 + prevalent coronary heart disease.

Table 3. Hazard ratios for incident heart failure at 10, 20, and 30 years since mtDNA copy number measurement.

	Year 10	Year 20	Year 30
Quintile 1	1 (reference)	1 (reference)	1 (reference)
Quintile 2	0.90 (0.78–1.03)	0.94 (0.83–1.08)	0.97 (0.82–1.14)
Quintile 3	0.78 (0.66–0.93)	0.87 (0.75–1.02)	0.91 (0.72–1.16)
Quintile 4	0.76 (0.61–0.93)	0.89 (0.74–1.06)	0.95 (0.69–1.32)
Quintile 5	0.68 (0.53–0.88)	0.84 (0.69–1.02)	0.92 (0.61–1.39)
90th vs. 10th	0.65 (0.54–0.79)	0.89 (0.76–1.04)	0.99 (0.72–1.37)
percentile			

Time-dependent model adjusted for age, sex, race, enrollment center, body mass index, smoking, alcohol intake, total cholesterol, HDL-cholesterol, cholesterol medication, hypertension, diabetes, and prevalent coronary heart disease.

Table 4. Hazard ratios for incident heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) by quintiles of mitochondrial DNA copy number.

mtDNA-CN	N events / N total	Incidence rate per 1,000	Model 1	Model 2	Model 3	Model 4
HFpEF						
Overall	564 / 8,892	6.2				
Quintile 1	103 / 1,701	6.0	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Quintile 2	111 / 1,776	6.1	1.05 (0.80–1.37)	1.09 (0.83–1.43)	1.10 (0.94–1.45)	1.12 (0.85–1.47)
Quintile 3	120 / 1,762	6.6	1.16 (0.89–1.51)	1.16 (0.89–1.51)	1.17 (0.90–1.53)	1.17 (0.90–1.53)
Quintile 4	122 / 1,846	6.2	1.12 (0.86–1.45)	1.15 (0.88–1.49)	1.17 (0.89–1.52)	1.13 (0.86–1.48)
Quintile 5	108 / 1,807	5.8	1.01 (0.77–1.32)	1.02 (0.78–1.34)	1.02 (0.77–1.34)	0.97 (0.74–1.29)
P for trend			0.80	0.76	0.77	0.89
HFrEF						
Overall	504 / 8,892	5.5				
Quintile 1	114 / 1,701	6.7	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Quintile 2	103 / 1,776	5.7	0.87 (0.66–1.13)	0.88 (0.68–1.16)	0.88 (0.67–1.15)	0.88 (0.67–1.16)
Quintile 3	94 / 1,762	5.1	0.80 (0.64–1.05)	0.81 (0.62–1.07)	0.81 (0.62–1.07)	0.79 (0.59–1.04)
Quintile 4	100 / 1,846	5.1	0.82 (0.63–1.07)	0.85 (0.64–1.11)	0.85 (0.65–1.12)	0.87 (0.66–1.15)
Quintile 5	93 / 1,807	5.0	0.76 (0.58–1.00)	0.77 (0.58–1.02)	0.77 (0.58–1.02)	0.80 (0.60–1.05)
P for trend			0.06	0.07	0.08	0.14

Abbreviations: HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; and mtDNA-CN, mitochondrial DNA copy number.

Model 1: Adjusted for age, sex, and race/enrollment center; Model 2: Model 1 + body mass index, smoking, alcohol intake, and physical activity; Model 3: Model 2 + total cholesterol, HDL-cholesterol, cholesterol medication, hypertension, diabetes; Model 3 + prevalent coronary heart disease.

Figure 1. Hazard ratios for incident heart failure by levels of mitochondrial DNA copy number.






Figure 2. Hazard ratios for incident heart failure comparing the 90th to the 10th percentile of mitochondrial DNA copy number in selected subgroups.

	Events / Total N	HR (95% CI)		P-interaction
Age			 	
< 60 ≥ 60	1,083 / 6,743 1,144 / 4,068	0.72 (0.63-0.83) 0.84 (0.73-0.95)		0.14
Sex				
Men Women	1,117 / 4,904 1,110 / 5,898	0.79 (0.69-0.91) 0.73 (0.64-0.84)		0.48
Race				
White Black	1,662 / 8,551 565 / 2,251	0.79 (0.70-0.88) 0.69 (0.57-0.83)	_=	0.23
Smoking				
Never Former Current	713 / 4,165 886 / 4,460 620 / 2,456	0.71 (0.59-0.84) 0.81 (0.70-0.95) 0.75 (0.62-0.90)		0.22 0.67
Alcohol				
Never Former Current	496 / 2,271 575 / 2,239 1,148 / 6,270	0.63 (0.52-0.76) 0.72 (0.60-0.87) 0.86 (0.75-0.99)		0.3 0.01
ВМІ				
Under or norma Overweight Obese	855 / 4,334 860 / 3,039	0.68 (0.55-0.83) 0.87 (0.75-1.02) 0.71 (0.61-0.83)		0.05 0.73
Prevalent CHE)			
No Yes	1,930 / 10,074 237 / 514	0.75 (0.67-0.83) 0.87 (0.66-1.15)		0.29
Overall	2,227 / 10,802	0.76 (0.69, 0.84)		
			0.5	1.5

Figure 3. Time-dependent hazard ratios for incident heart failure comparing the 90th to the 10th percentile of mitochondrial DNA copy number.





	Events / Total N	HR (95% CI)			P-interaction
Age			1		
< 60	1,083 / 6,743	0.72 (0.63-0.83)			0.14
≥ 60	1,144 / 4,068	0.84 (0.73-0.95)			
Sex			 		
Men	1,117 / 4,904	0.79 (0.69-0.91)			0.48
Women	1,110 / 5,898	0.73 (0.64-0.84)			
Race			[
White	1,662 / 8,551	0.79 (0.70-0.88)	-		0.23
Black	565 / 2,251	0.69 (0.57-0.83)			
Smoking					
Never	713 / 4,165	0.71 (0.59-0.84)			
Former	886 / 4,460	0.81 (0.70-0.95)			0.22
Current	620 / 2,456	0.75 (0.62-0.90)			0.67
Alcohol			 		
Never	496 / 2,271	0.63 (0.52-0.76)			
Former	575 / 2,239	0.72 (0.60-0.87)			0.3
Current	1,148 / 6,270	0.86 (0.75-0.99)			0.01
ВМІ			[[
Under or norma		0.68 (0.55-0.83)			
Overweight	855 / 4,334	0.87 (0.75-1.02)			0.05
Obese	860 / 3,039	0.71 (0.61-0.83)			0.73
Prevalent CHI)				
No	1,930 / 10,074	0.75 (0.67-0.83)			0.29
Yes	237 / 514	0.87 (0.66-1.15)		•	
Overall	2,227 / 10,802	0.76 (0.69, 0.84)			
			1		
			0.5 1	1 5	
			0.5 1	1.5	

